title: Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
authors.affiliation: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
authors.forename: Hossein
authors.initials: H
authors.lastname: Borghaei
authors.forename: Michael
authors.initials: M
authors.lastname: Millenson
authors.forename: Russell
authors.initials: R
authors.lastname: Schilder
authors.forename: Mitchell
authors.initials: M
authors.lastname: Alden
authors.forename: Andre
authors.initials: A
authors.lastname: Rogatko
authors.forename: Hao
authors.initials: H
authors.lastname: Wang
authors.forename: Kristin
authors.initials: K
authors.lastname: Padavic-Shaller
authors.forename: Mitchell R
authors.initials: MR
authors.lastname: Smith
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004961:Estramustine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D012008:Recurrence; D015996:Survival Rate
chemical_list: D004961:Estramustine; D017239:Paclitaxel